CL2014002773A1 - Una forma de dosificacion subcutanea de una composicion farmaceutica de un factor de coagulacion sanguinea seleccionado de factor vii, viia, viii, ix, x, xa, xi, xiii, v, factor de von willebrand y proteina c, conjugado con una molecula de polietilenglicol (peg), en donde la dosificacion del factor es de 100 y 250 ui/kg o 25 y 50 ui/kg, y en donde la molecula de peg se conjuga directa o indirectamente. - Google Patents

Una forma de dosificacion subcutanea de una composicion farmaceutica de un factor de coagulacion sanguinea seleccionado de factor vii, viia, viii, ix, x, xa, xi, xiii, v, factor de von willebrand y proteina c, conjugado con una molecula de polietilenglicol (peg), en donde la dosificacion del factor es de 100 y 250 ui/kg o 25 y 50 ui/kg, y en donde la molecula de peg se conjuga directa o indirectamente.

Info

Publication number: CL2014002773A1
Authority: CL; Chile
Prior art keywords: factor; peg; conjugated; molecule; viia
Prior art date: 2012-04-16

Application number

CL2014002773A

Other languages

English (en)

Spanish (es)

Inventor

William Henry

Garraway Richard Wolf

Michael James Earl

John Charles Mayo

Original Assignee

Cantab Biopharmaceuticals Patents Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-04-16

Filing date

2014-10-15

Publication date

2015-01-16

2012-04-16 Priority claimed from GBGB1206628.8A external-priority patent/GB201206628D0/en

2012-08-01 Priority claimed from GBGB1213712.1A external-priority patent/GB201213712D0/en

2012-08-22 Priority claimed from GBGB1214985.2A external-priority patent/GB201214985D0/en

2014-10-15 Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd

2015-01-16 Publication of CL2014002773A1 publication Critical patent/CL2014002773A1/es

Links

108010039209 Blood Coagulation Factors Proteins 0.000 title 1
102000015081 Blood Coagulation Factors Human genes 0.000 title 1
239000002202 Polyethylene glycol Substances 0.000 title 1
239000003114 blood coagulation factor Substances 0.000 title 1
229940019700 blood coagulation factors Drugs 0.000 title 1
229940012413 factor vii Drugs 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
229920001223 polyethylene glycol Polymers 0.000 title 1
229960000856 protein c Drugs 0.000 title 1
239000006203 subcutaneous dosage form Substances 0.000 title 1
108010047303 von Willebrand Factor Proteins 0.000 title 1
102100036537 von Willebrand factor Human genes 0.000 title 1
229960001134 von willebrand factor Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Hematology (AREA)
Zoology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Oncology (AREA)
Dispersion Chemistry (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Inorganic Chemistry (AREA)
Endocrinology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL2014002773A 2012-04-16 2014-10-15 Una forma de dosificacion subcutanea de una composicion farmaceutica de un factor de coagulacion sanguinea seleccionado de factor vii, viia, viii, ix, x, xa, xi, xiii, v, factor de von willebrand y proteina c, conjugado con una molecula de polietilenglicol (peg), en donde la dosificacion del factor es de 100 y 250 ui/kg o 25 y 50 ui/kg, y en donde la molecula de peg se conjuga directa o indirectamente. CL2014002773A1 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB1206628.8A GB201206628D0 (en)	2012-04-16	2012-04-16	Subcutaneous administration of PEGylated blood clotting factors
GBGB1213712.1A GB201213712D0 (en)	2012-08-01	2012-08-01	Modified therapeutic agents
GBGB1214985.2A GB201214985D0 (en)	2012-08-22	2012-08-22	Modified therapeutic agents

Publications (1)

Publication Number	Publication Date
CL2014002773A1 true CL2014002773A1 (es)	2015-01-16

Family

ID=48190923

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014002773A CL2014002773A1 (es)	2012-04-16	2014-10-15	Una forma de dosificacion subcutanea de una composicion farmaceutica de un factor de coagulacion sanguinea seleccionado de factor vii, viia, viii, ix, x, xa, xi, xiii, v, factor de von willebrand y proteina c, conjugado con una molecula de polietilenglicol (peg), en donde la dosificacion del factor es de 100 y 250 ui/kg o 25 y 50 ui/kg, y en donde la molecula de peg se conjuga directa o indirectamente.

Country Status (29)

Country	Link
US (2)	US20150086524A1 (2)
EP (1)	EP2838566A2 (2)
JP (3)	JP2015512927A (2)
KR (1)	KR102137290B1 (2)
CN (1)	CN104411335A (2)
AP (1)	AP2014008049A0 (2)
AU (3)	AU2013248296A1 (2)
BR (1)	BR112014025737A2 (2)
CA (1)	CA2869993C (2)
CL (1)	CL2014002773A1 (2)
CO (1)	CO7151496A2 (2)
CR (1)	CR20140475A (2)
EA (1)	EA033469B1 (2)
EC (1)	ECSP14023048A (2)
GB (3)	GB2516388A (2)
GE (1)	GEP201706716B (2)
HK (1)	HK1200695A1 (2)
IL (1)	IL235129B (2)
IN (1)	IN2014DN08598A (2)
MD (1)	MD20140123A2 (2)
MX (2)	MX2014012512A (2)
MY (1)	MY190257A (2)
NI (1)	NI201400122A (2)
NZ (1)	NZ701205A (2)
PE (1)	PE20150226A1 (2)
PH (1)	PH12014502314B1 (2)
SG (1)	SG11201406492YA (2)
WO (1)	WO2013156488A2 (2)
ZA (1)	ZA201407370B (2)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN109498815B (zh) *	2013-12-30	2022-07-22	江苏众红生物工程创药研究院有限公司	重组人激肽释放酶的化学修饰物及其应用
GB201417589D0 (en) *	2014-10-06	2014-11-19	Cantab Biopharmaceuticals Patents Ltd	Pharmaceutical Formulations
FR3034669B1 (fr) *	2015-04-07	2020-02-14	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Nouvelle utilisation du facteur von willebrand
US20180169297A1 (en) *	2015-06-12	2018-06-21	Laboratoire Français Du Fractionnement Et Des Biotechnologies	Injectable composition of factor vii and fillers
GB201518172D0 (en)	2015-10-14	2015-11-25	Cantab Biopharmaceuticals Patents Ltd	Colloidal particles for use in medicine
GB201518170D0 (en)	2015-10-14	2015-11-25	Cantab Biopharmaceuticals Patents Ltd	Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en)	2015-10-14	2015-11-25	Cantab Biopharmaceuticals Patents Ltd	Colloidal particles for topical administration with therapeutic agent
CN109998994B (zh) *	2018-02-13	2021-12-07	四川大学	包含药物的柔性脂质体及其制备方法
US20230190881A1 (en)	2020-02-17	2023-06-22	Biotest Ag	Subcutaneous administration of factor viii
CN115443147A (zh) *	2020-04-23	2022-12-06	伊莱利利公司	抗体的皮下吸收和生物利用度

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1479268A (en)	1973-07-05	1977-07-13	Beecham Group Ltd	Pharmaceutical compositions
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
CH596313A5 (2)	1975-05-30	1978-03-15	Battelle Memorial Institute
US4414147A (en)	1981-04-17	1983-11-08	Massachusetts Institute Of Technology	Methods of decreasing the hydrophobicity of fibroblast and other interferons
US4496689A (en)	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
WO1987000056A1 (en)	1985-06-26	1987-01-15	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
AU5858690A (en) *	1989-06-14	1991-01-08	Cetus Corporation	Polymer/antibiotic conjugate
AU5098193A (en)	1992-09-01	1994-03-29	Berlex Laboratories, Inc.	Glycolation of glycosylated macromolecules
JP3866279B2 (ja)	1992-09-28	2007-01-10	リサーチコーポレイションテクノロジーズ，インコーポレイテッド	ペプチド連結用の新規な試薬
US5621039A (en) *	1993-06-08	1997-04-15	Hallahan; Terrence W.	Factor IX- polymeric conjugates
IL113010A (en) *	1994-03-31	1999-10-28	Pharmacia & Upjohn Ab	Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
JPH0892294A (ja) *	1994-09-29	1996-04-09	Teijin Ltd	ヒト活性化プロテインｃ誘導体
US5693609A (en)	1994-11-17	1997-12-02	Eli Lilly And Company	Acylated insulin analogs
CA2177644A1 (en) *	1995-05-31	1996-12-01	Peter D. Senter	Polymeric prodrugs for beta-lactamase and uses thereof
SE9503380D0 (sv) *	1995-09-29	1995-09-29	Pharmacia Ab	Protein derivatives
WO1998032466A1 (en)	1997-01-29	1998-07-30	Polymasc Pharmaceuticals Plc	Pegylation process
AU2605099A (en) *	1998-02-25	1999-09-15	Micrologix Biotech, Inc.	Indolicidin and cationic peptides conjugated with polymers
CN100488562C (zh) *	2000-02-11	2009-05-20	拜耳医药保健有限公司	凝血因子VⅡ或VⅡa样分子
ES2449224T3 (es)	2000-05-03	2014-03-18	Novo Nordisk Health Care Ag	Administración subcutánea del Factor de coagulación VII
US20030211094A1 (en) *	2001-06-26	2003-11-13	Nelsestuen Gary L.	High molecular weight derivatives of vitamin k-dependent polypeptides
WO2004000366A1 (en) *	2002-06-21	2003-12-31	Novo Nordisk Health Care Ag	Pegylated factor vii glycoforms
MXPA04012496A (es) *	2002-06-21	2005-09-12	Novo Nordisk Healthcare Ag	Glicoformos del factor vii pegilados.
LT1596887T (lt) *	2003-02-26	2022-04-25	Nektar Therapeutics	Polimero-faktoriaus viii fragmento konjugatai
AU2004228793B2 (en) *	2003-04-08	2009-10-08	Yeda Research And Development Co. Ltd.	Reversible pegylated drugs
US20130137157A1 (en) *	2003-04-09	2013-05-30	Novo Nordisk A/S	Glycopegylated factor vii and factor viia
GB0316294D0 (en)	2003-07-11	2003-08-13	Polytherics Ltd	Conjugated biological molecules and their preparation
US20060198819A1 (en)	2003-08-08	2006-09-07	Novo Nordisk Healthcare A/G	Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
US7612066B2 (en)	2004-03-04	2009-11-03	Eisai R&D Management Co., Ltd.	Composition containing benzamidine derivative and method for stabilizing benzamidine derivative
KR101100059B1 (ko) *	2004-06-30	2011-12-29	넥타르 테라퓨틱스	중합체인자 ｉｘ 부분의 접합체
US20090176967A1 (en)	2004-08-02	2009-07-09	Novo Nordisk Healthcare A/G	Conjugation of FVII
EP1891231A4 (en)	2005-05-25	2011-06-22	Novo Nordisk As	GLYCOPEGYLATED FACTOR IX
WO2006134173A2 (en)	2005-06-17	2006-12-21	Novo Nordisk Health Care Ag	Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
BRPI0614839A2 (pt) *	2005-08-19	2009-05-19	Neose Technologies Inc	fator vii e fator viia glicopeguilados
NZ572050A (en) *	2006-03-31	2011-09-30	Baxter Int	Factor VIII conjugated to polyethylene glycol
EP2059527B1 (en)	2006-09-01	2014-12-03	Novo Nordisk Health Care AG	Modified glycoproteins
CN103804489A (zh)	2006-12-15	2014-05-21	巴克斯特国际公司	具有延长的体内半衰期的因子VIIa-聚唾液酸结合物
US8133865B2 (en) *	2006-12-27	2012-03-13	Nektar Therapeutics	von Willebrand factor- and factor VIII-polymer conjugates having a releasable linkage
WO2008081024A1 (en)	2007-01-03	2008-07-10	Novo Nordisk Health Care Ag	Subcutaneous administration of coagulation factor viia-related popypeptdes
WO2008119815A1 (en) *	2007-04-02	2008-10-09	Novo Nordisk A/S	Subcutaneous administration of coagulation factor ix
SG174077A1 (en)	2007-04-13	2011-09-29	Catalyst Biosciences Inc	Modified factor vii polypetides and uses thereof
EP2014299A1 (en)	2007-07-11	2009-01-14	Novo Nordisk A/S	Subcutaneous administration of coagulation factor VII
ES2597849T3 (es)	2007-10-09	2017-01-23	Polytherics Limited	Proteínas y péptidos conjugados novedosos
EA201370191A1 (ru)	2007-10-16	2014-05-30	Фармасайкликс, Инк.	КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ
ES2476690T3 (es)	2008-02-27	2014-07-15	Novo Nordisk A/S	Moléculas conjugadas del Factor VIII
TWI465247B (zh)	2008-04-11	2014-12-21	Catalyst Biosciences Inc	經修飾的因子ｖｉｉ多肽和其用途
CN102065887A (zh) *	2008-04-16	2011-05-18	拜耳医药保健有限公司	因子ix的定点修饰
BRPI0911350A2 (pt) *	2008-04-24	2017-12-05	Celtic Pharma Peg Ltd	conjugado de polietileno glicol, método para tratar hemofilia b, e, método para reduzir o risco de doenças ou condições.
CN102083459A (zh) *	2008-05-23	2011-06-01	诺沃-诺迪斯克保健股份有限公司	包括含有peg化的gla-结构域的蛋白质的低粘度组合物
DK2326349T3 (en)	2008-07-21	2015-05-26	Polytherics Ltd	Novel Reagents and Methods for Conjugation of Biological Molecules
PL2349341T3 (pl) *	2008-10-15	2014-03-31	Baxalta Inc	Pegylacja rekombinowanych czynników krzepnięcia krwi w obecności przeciwciał zwierzęcych
JP5785872B2 (ja) *	2008-10-17	2015-09-30	バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒＩｎｔｅｒｎａｔｉｏｎａｌＩｎｃｏｒｐ０Ｒａｔｅｄ	低度の水溶性ポリマーを含む改変血液因子
US20120121613A1 (en) *	2009-01-19	2012-05-17	Bayer Healthcare Llc	Protein conjugate having an endopeptidase- cleavable bioprotective moiety
KR101759300B1 (ko) *	2009-07-27	2017-07-31	리폭센 테크놀로지즈 리미티드	비혈액 응고 단백질의 글리코폴리시알화
EP2536753B1 (en) *	2010-02-16	2017-12-20	Novo Nordisk A/S	Factor viii molecules with reduced vwf binding
GB201007356D0 (en) *	2010-04-30	2010-06-16	Leverton Licence Holdings Ltd	Conjugated factor VIIa
GB201007357D0 (en)	2010-04-30	2010-06-16	Leverton Licence Holdings Ltd	Conjugated factor VIII
PL2598172T3 (pl) *	2010-07-30	2019-09-30	Baxalta GmbH	Katalizatory nukleofilowe do wiązania oksymowego
WO2012088123A1 (en) *	2010-12-22	2012-06-28	Nektar Therapeutics	Polymer-factor vii moiety conjugates

2013
- 2013-04-16 GB GB1418864.3A patent/GB2516388A/en not_active Withdrawn
- 2013-04-16 AP AP2014008049A patent/AP2014008049A0/xx unknown
- 2013-04-16 MX MX2014012512A patent/MX2014012512A/es unknown
- 2013-04-16 HK HK15100881.5A patent/HK1200695A1/xx unknown
- 2013-04-16 SG SG11201406492YA patent/SG11201406492YA/en unknown
- 2013-04-16 MY MYPI2014002900A patent/MY190257A/en unknown
- 2013-04-16 MD MD20140123A patent/MD20140123A2/ro unknown
- 2013-04-16 WO PCT/EP2013/057928 patent/WO2013156488A2/en not_active Ceased
- 2013-04-16 EP EP13719043.5A patent/EP2838566A2/en not_active Withdrawn
- 2013-04-16 IN IN8598DEN2014 patent/IN2014DN08598A/en unknown
- 2013-04-16 AU AU2013248296A patent/AU2013248296A1/en not_active Abandoned
- 2013-04-16 EA EA201491702A patent/EA033469B1/ru unknown
- 2013-04-16 PE PE2014001639A patent/PE20150226A1/es active IP Right Grant
- 2013-04-16 KR KR1020147031042A patent/KR102137290B1/ko active Active
- 2013-04-16 CN CN201380027958.3A patent/CN104411335A/zh active Pending
- 2013-04-16 CA CA2869993A patent/CA2869993C/en active Active
- 2013-04-16 US US14/394,437 patent/US20150086524A1/en not_active Abandoned
- 2013-04-16 GB GBGB1910184.9A patent/GB201910184D0/en not_active Ceased
- 2013-04-16 GE GEAP201313632A patent/GEP201706716B/en unknown
- 2013-04-16 IL IL235129A patent/IL235129B/en unknown
- 2013-04-16 BR BR112014025737A patent/BR112014025737A2/pt not_active Application Discontinuation
- 2013-04-16 GB GBGB1910190.6A patent/GB201910190D0/en not_active Ceased
- 2013-04-16 JP JP2015504987A patent/JP2015512927A/ja active Pending
- 2013-04-16 NZ NZ701205A patent/NZ701205A/en not_active IP Right Cessation
2014
- 2014-10-10 ZA ZA2014/07370A patent/ZA201407370B/en unknown
- 2014-10-14 CR CR20140475A patent/CR20140475A/es unknown
- 2014-10-15 PH PH12014502314A patent/PH12014502314B1/en unknown
- 2014-10-15 NI NI201400122A patent/NI201400122A/es unknown
- 2014-10-15 CL CL2014002773A patent/CL2014002773A1/es unknown
- 2014-10-16 EC ECIEPI201423048A patent/ECSP14023048A/es unknown
- 2014-10-16 MX MX2020014208A patent/MX2020014208A/es unknown
- 2014-11-14 CO CO14252826A patent/CO7151496A2/es unknown
2017
- 2017-08-30 US US15/691,090 patent/US11351112B2/en active Active
- 2017-09-06 JP JP2017171545A patent/JP6550107B2/ja not_active Expired - Fee Related
2018
- 2018-01-05 AU AU2018200111A patent/AU2018200111B2/en not_active Ceased
2019
- 2019-04-05 JP JP2019073048A patent/JP2019131593A/ja active Pending
2020
- 2020-02-06 AU AU2020200842A patent/AU2020200842A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2869993A1 (en)	2013-10-24
MD20140123A2 (ro)	2015-04-30
CO7151496A2 (es)	2014-12-29
CN104411335A (zh)	2015-03-11
GB201910190D0 (en)	2019-08-28
NI201400122A (es)	2016-12-02
PH12014502314A1 (en)	2015-01-12
MX2014012512A (es)	2015-01-15
WO2013156488A3 (en)	2014-01-16
CR20140475A (es)	2015-01-23
CA2869993C (en)	2023-05-23
KR20140146171A (ko)	2014-12-24
GB201910184D0 (en)	2019-08-28
US20180036229A1 (en)	2018-02-08
JP6550107B2 (ja)	2019-07-24
IN2014DN08598A (2)	2015-05-22
AU2020200842A1 (en)	2020-02-27
US11351112B2 (en)	2022-06-07
AP2014008049A0 (en)	2014-11-30
MY190257A (en)	2022-04-11
EA033469B1 (ru)	2019-10-31
BR112014025737A2 (pt)	2017-07-04
KR102137290B1 (ko)	2020-07-23
GEP201706716B (en)	2017-08-10
PE20150226A1 (es)	2015-02-14
IL235129A0 (en)	2014-12-31
AU2018200111B2 (en)	2019-11-07
NZ701205A (en)	2016-02-26
JP2018024684A (ja)	2018-02-15
WO2013156488A2 (en)	2013-10-24
EA201491702A1 (ru)	2015-03-31
JP2019131593A (ja)	2019-08-08
US20150086524A1 (en)	2015-03-26
MX2020014208A (es)	2021-03-09
SG11201406492YA (en)	2014-11-27
AU2018200111A1 (en)	2018-01-25
GB2516388A (en)	2015-01-21
ZA201407370B (en)	2017-09-27
EP2838566A2 (en)	2015-02-25
HK1200695A1 (en)	2015-08-14
GB201418864D0 (en)	2014-12-03
JP2015512927A (ja)	2015-04-30
IL235129B (en)	2022-06-01
ECSP14023048A (es)	2015-11-30
AU2013248296A1 (en)	2014-11-13
PH12014502314B1 (en)	2020-01-31

Publication	Publication Date	Title
CL2014002773A1 (es)	2015-01-16	Una forma de dosificacion subcutanea de una composicion farmaceutica de un factor de coagulacion sanguinea seleccionado de factor vii, viia, viii, ix, x, xa, xi, xiii, v, factor de von willebrand y proteina c, conjugado con una molecula de polietilenglicol (peg), en donde la dosificacion del factor es de 100 y 250 ui/kg o 25 y 50 ui/kg, y en donde la molecula de peg se conjuga directa o indirectamente.
CY1124436T1 (el)	2022-07-22	Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1123675T1 (el)	2021-05-05	Πολυαιθυλενογλυκολιωμενου φαρμακου-συνδετες για βελτιωμενες φαρμακοκινητικες προϊοντος συζευξης προσδετη-φαρμακου
EP3835296A4 (en)	2022-05-18	KETOAMIDE COMPOUND AND METHOD FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF
MX2020000083A (es)	2020-08-06	Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
CY1121881T1 (el)	2020-10-14	Φαρμακοτεχνικη μορφη που περιεχει σταθερη αναλογια ινσουλινης glargine/λιξισενατιδης
MY160922A (en)	2017-03-31	Polyethylene glycol conjugated blood coagulation factor vii
PE20140616A1 (es)	2014-05-24	Composicion que comprende aflibercept, acido folinico, 5-fluorouracilo (5-fu) e irinotecan (folfiri)
EP2983659A4 (en)	2016-12-14	ACTIVE DERIVATIVE POLYMER AND USES THEREOF
EA201890417A1 (ru)	2018-08-31	Генетически кодируемые, внутренне неупорядоченные полимеры-"невидимки" для доставки и способы их применения
CL2014001858A1 (es)	2014-09-26	Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer.
CY1120098T1 (el)	2018-12-12	Συνθεσεις που περιεχουν βορτιοξετινη και δονεπεζιλη
MX381365B (es)	2025-03-12	Composiciones de resina reciclada y dispositivos medicos desechables preparados a partir de las anteriores.
EP3318282A4 (en)	2019-05-22	AGGREGATE COMPOSITION CARRIER AND COMPOSITION THEREOF
MY160510A (en)	2017-03-15	Polyethylene gycol conjugated blood coagulation factor viia
CY1119036T1 (el)	2018-01-10	Νεοι αγωνιστες του υποδοχεα τυπου 2 της αγγειοτενσινης (ατ2) και χρησεις τους
EP3556352A4 (en)	2020-07-22	COMPOSITION OF AMPHIPHILIC SEQUENCED COPOLYMER WITH IMPROVED MICELLAR STABILITY AND PHARMACEUTICAL COMPOSITION COMPRISING IT
CL2012003322A1 (es)	2014-03-28	Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
AR095527A1 (es)	2015-10-21	Formulaciones de polipéptido fc-factor ix
MX2017014503A (es)	2018-08-01	Polipeptidos de factor de von willebrand truncado para tratar hemofilia.
MX389026B (es)	2025-03-20	Una composicion farmaceutica y el uso de la misma.
CY1121566T1 (el)	2020-05-29	Νευροπροστατευτικο και ενδειξη αυτου
IL269962A (en)	2019-12-31	Article of manufacture comprising local anesthetic, buffer, and glycosaminoglycan in syringe with improved stability
EA201691860A1 (ru)	2017-03-31	Пептидный медикамент в виде сухого порошка
MX375186B (es)	2025-03-06	Composiciones de anfetamina transdérmica estable y métodos de fabricación.